{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:34:51Z","timestamp":1791153291939,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.vaccine.2011.08.040","type":"journal-article","created":{"date-parts":[[2011,8,21]],"date-time":"2011-08-21T16:23:43Z","timestamp":1313943823000},"page":"8094-8100","source":"Crossref","is-referenced-by-count":12,"title":["Recombinant Shiga toxin B subunit elicits protection against Shiga toxin via mixed Th type immune response in mice"],"prefix":"10.1016","volume":"29","author":[{"given":"Pallavi","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manglesh Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamini","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Om","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram Kumar","family":"Dhaked","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.08.040_bib0005","first-page":"651","article-title":"Global burden of Shigella infections: implication for vaccine development and implementation of control strategies","volume":"77","author":"Kotloff","year":"1999","journal-title":"Bull WHO"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0010","unstructured":"www.cdc.gov\/ecoli\/2011\/ecolio104."},{"key":"10.1016\/j.vaccine.2011.08.040_bib0015","doi-asserted-by":"crossref","first-page":"15484","DOI":"10.1016\/S0021-9258(18)82282-7","article-title":"Endothelial heterogeneity in Shiga toxin receptors and responses","volume":"268","author":"ObrigTG","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000171588","article-title":"Enterohemorrhagic Escherichia coli: a family of emerging pathogens","volume":"15","author":"Noel","year":"1997","journal-title":"Dig Dis"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0025","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/infdis\/151.5.775","article-title":"The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli","volume":"151","author":"Karmali","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0030","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1084\/jem.160.6.1767","article-title":"Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies","volume":"160","author":"Donohue-Rolfe","year":"1984","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0035","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/IAI.62.5.1768-1775.1994","article-title":"Evidence that the A2 fragment of Shiga-like toxin type I is required for holotoxin integrity","volume":"62","author":"Austin","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0040","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0021-9258(19)75706-8","article-title":"Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1","volume":"262","author":"Lindberg","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1432-1033.1988.tb13756.x","article-title":"The site of action of a Verotoxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes: RNA N-glycosidase activity of the toxins","volume":"171","author":"Endo","year":"1988","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0050","doi-asserted-by":"crossref","first-page":"9394","DOI":"10.1021\/bi980424u","article-title":"Shiga toxin attacks bacterial ribosomes as effectively as eucaryotic ribosomes","volume":"37","author":"Suh","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0055","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000185286","article-title":"Verotoxin receptor glycolipid in human renal tissue","volume":"51","author":"Boyd","year":"1989","journal-title":"Nephron"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0060","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1128\/IAI.73.7.4088-4097.2005","article-title":"Nontoxic Shiga toxin derivatives from Escherichia coli possesses adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation","volume":"73","author":"Ohmura","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0065","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1128\/IAI.57.12.3888-3893.1989","article-title":"Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies","volume":"57","author":"Donohue-Rolfe","year":"1989","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0070","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/IAI.56.8.1926-1933.1988","article-title":"Affinity purification and characterization of Shiga-like toxin II and production of toxin specific monoclonal antibodies","volume":"56","author":"Downes","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0075","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1128\/IAI.56.6.1618-1624.1988","article-title":"Synthetic peptides of Shiga toxin B subunit induce antibodies which neutralize its biological activity","volume":"56","author":"Harari","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0080","first-page":"11","article-title":"Production and characterization of monoclonal antibodies with therapeutic potential against Shiga toxin","volume":"33","author":"Islam","year":"1990","journal-title":"J Clin Lab Immunol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0085","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1128\/IAI.01247-06","article-title":"The 13C4 Monoclonal antibody that neutralizes Shiga toxin type1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide","volume":"74","author":"Smith","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0090","first-page":"54","article-title":"A challenge model for Shigella dysenteriae 1 in cynomolgus monkeys (Macaca fascicularis)","volume":"60","author":"Steven","year":"2010","journal-title":"Comp Med"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0095","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1128\/IAI.63.1.289-296.1995","article-title":"Persistence of local cytokine production in Shigellosis in acute and convalescent stages","volume":"63","author":"Rubhana","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0100","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/intimm\/dxg118","article-title":"The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization","volume":"15","author":"Haicheur","year":"2003","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0105","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1016\/j.vaccine.2006.02.035","article-title":"Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2","volume":"24","author":"Smith","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0110","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2174\/092986610791190291","article-title":"Antibodies against recombinant Shiga toxin subunit B neutralize Shiga toxin toxicity in HeLa cells","volume":"17","author":"Gupta","year":"2010","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CVI.00399-07","article-title":"Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin B subunit","volume":"15","author":"Zhu","year":"2008","journal-title":"Clin Vac Immunol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0120","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1128\/JCM.39.6.2272-2279.2001","article-title":"Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome","volume":"39","author":"Ludwig","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0125","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1128\/IAI.59.3.750-757.1991","article-title":"Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter the action of the toxin","volume":"59","author":"Boyd","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0130","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1128\/IAI.72.2.889-895.2004","article-title":"Production of secretory immunoglobulin A against Shiga toxin-binding subunits in mice by mucosal immunization","volume":"72","author":"Imai","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0135","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.4049\/jimmunol.181.6.4131","article-title":"Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas","volume":"181","author":"Betting","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1157\/13045071","article-title":"Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaica","volume":"31","author":"Garcia-Selles","year":"2003","journal-title":"Allergol Immunopathol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0145","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/30989","article-title":"A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell","volume":"393","author":"Ridge","year":"1998","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2011.08.040_bib0150","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.4049\/jimmunol.168.3.1172","article-title":"Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains","volume":"168","author":"Machy","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0155","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1128\/IAI.69.1.579-583.2001","article-title":"Mouse toxicity and cytokine release by verotoxin 1 B subunit mutants","volume":"69","author":"Wolski","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0160","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/BF00868714","article-title":"Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura","volume":"9","author":"Karpman","year":"1995","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0165","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.micpath.2003.11.004","article-title":"Escherichia coli Shiga toxin 1 and TNF-\u03b1 induce cytokine release by human cerebral microvascular endothelial cells","volume":"36","author":"Eisenhauer","year":"2004","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0170","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1432-1033.1987.tb13452.x","article-title":"Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6)","volume":"168","author":"Van Damme","year":"1987","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0175","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0008-8749(90)90074-2","article-title":"The role of human interleukin-6 in B-cell isotype regulation and differentiation","volume":"125","author":"Bertolini","year":"1990","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0180","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.4049\/jimmunol.151.6.2895","article-title":"Heterogeneous mechanisms of human cytotoxic T lymphocyte generation. II. Differential effects of IL-6 on the helper cell-independent generation of CTL from CD8+ precursor subpopulations","volume":"151","author":"Bass","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0185","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.4049\/jimmunol.143.4.1206","article-title":"IFN-beta 2\/IL-6 augments the activity of human natural killer cells","volume":"143","author":"Luger","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0190","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.iy.08.040190.001511","article-title":"Lymphokine control of in vivo immunoglobulin isotype selection","volume":"8","author":"Finkelman","year":"1990","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0195","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/35021239","article-title":"Vaccines against intracellular infections requiring cellular immunity","volume":"406","author":"Seder","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0200","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1016\/S0264-410X(01)00193-1","article-title":"Towards the rational design of Th1 adjuvants","volume":"19","author":"Moingeon","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0167-5699(93)90318-F","article-title":"Towards a comprehensive view of immunoglobulin class switching","volume":"14","author":"Snapper","year":"1993","journal-title":"Immunol Today"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0210","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0091-6749(96)80146-1","article-title":"Update on cytokines","volume":"3","author":"Boris","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2011.08.040_bib0215","first-page":"53","article-title":"Immune responses of mice immunized with active recombinant Shiga toxin and its derivatives","volume":"7","author":"Oloomi","year":"2008","journal-title":"Iran J Allergy Asthma Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11012710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11012710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T22:22:11Z","timestamp":1686262931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11012710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":43,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0264410X11012710"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.08.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}